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Abstract
Objectives: In this paper, we present a review of critical concepts and research perspectives and produce
recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion
from an expert panel appointed by the Italian Society of Hematology and the affiliate societies, Societa
Italiana di Ematologia Sperimentale and Gruppo Italiano Trapianto di Midollo Osseo. Methods:
Recommendations were produced using the Delphi process. Scientific evidence on pixantrone efficacy
was analyzed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)
methodology in the areas where at least one randomized trial was published. The following key issues
were addressed for practical recommendations: pixantrone monotherapy in aggressive relapsed or
refractory non-Hodgkin B-cell lymphomas and toxicity risk management in patients candidates to
pixantrone. Results and conclusions: After a balanced and value-oriented discussion, the panel agreed that
the benefit/risk profile was in favor of pixantrone in the treatment of adult patients with multiply relapsed
or refractory aggressive NHL B-cell lymphomas. Pixantrone was deemed to be contraindicated in patients
with uncontrolled cardiovascular disease. Despite a low rate of cardiotoxicity of pixantrone reported in
clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical
cardiac monitoring.
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Pixantrone is a novel aza-anthracenedione that in preclinical
settings showed a remarkable activity in lymphomas and leu-
kemias (1, 2). On May, 2012, the European Medicines
Agency (EMA) recommended the granting of a conditional
marketing authorization for pixantrone for the treatment of
patients with multiply relapsed aggressive NHL as
monotherapy (3, 4). In the main study submitted for this
application, a significant difference in response rate was
observed in favor of pixantrone, supported by the results of
secondary endpoints of median progression-free (PFS) and
overall survival (OS) times (5).
Pixantrone now represents a major advance in the treat-
ment of NHL; however, several uncertainties still remain on
the optimal use of the drug in the approved indication, in
particular on cardiotoxicity management. In addition, new
questions are emerging on the use of the drug early in the
treatment of NHL, as well as on its effectiveness as a combi-
nation therapy. In order to support the physicians in manag-
ing patients candidates to pixantrone, a consensus
development conference project on pixantrone was convened
under the sponsorship of the Italian Society of Hematology
and the affiliate societies Societa Italiana di Ematologia
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Sperimentale and Gruppo Italiano Trapianto di Midollo
Osseo.
Design and methods
Organization
Two chairmen (ST and GB) appointed a panel of seven
experts, selected for their expertise in research and clinical
practice of adult lymphoid malignancies or in clinical phar-
macology, hereafter called expert panel (EP). A clinician
with expertise in clinical epidemiology (GB) assured the
methodological appropriateness of the process.
GRADE use for evidence appraisal
We performed a structured literature search for English-
language publications using electronic databases such as
MEDLINE (2005–2014), EMBASE (2005–2014), reviews
including Cochrane Database of Systematic Reviews, and
the Cochrane Controlled Trials Register. References in
identified reports and reviews were screened to find addi-
tional relevant publications. Publications which measured
efficacy of pixantrone in persons with malignant lym-
phomas with or without a comparison group were
included. We used the Grades of Recommendation,
Assessment, Development, and Evaluation (GRADE)
methodology to rate confidence in estimates of effect for
each outcome (6).
The consensus process
During an initial meeting, the EP agreed on the areas of
major concern in the use of pixantrone by generating and
rank-ordering clinical key questions using the criterion of
clinical relevance, that is, impact on the management of
patients and risk of inappropriateness, through a Delphi
process (7). The candidate key questions that ranked high-
est formed the set of issues of the present document. Dur-
ing the first of four meetings, the EP examined the current
state of knowledge regarding pixantrone and was accounted
for the results of pixantrone critical appraisal. Each panelist
drafted statements that addressed the identified key ques-
tions, and the remaining panelists scored their agreement
with those statements and provided suggestions for rephras-
ing. For exploiting this phase of the process, the EP was
convened and three further consensus meetings were held
in Bologna, Italy. The overall goals of the meetings were
to reach a definite consensus over question-specific state-
ments for which there was disagreement during the first-
round postal phase. The nominal group technique was used
by which participants were first asked to comment in
round-robin fashion on their preliminary votes and then to
propose a new vote (8).
Results
Preclinical and clinical pharmacology
Pixantrone differs from mitoxantrone due to removal of the
hydroquinone moiety, insertion of a nitrogen heteroatom,
and substitution of (ethylamino)-diethylamino for (hydrox-
yethylamino)-ethylamino side chains. Such chemical modifi-
cations cause important effects on pixantrone activity. In
preclinical settings, pixantrone showed a limited efficacy in
cellular or animal models of solid malignancies but proved
remarkably active in lymphomas and leukemias. Pixantrone
also showed pharmacodynamics that were different from
mitoxantrone. Whereas mitoxantrone killed tumor cells
through topoisomerase IIa inhibition and consequent forma-
tion of DNA double-strand breaks, pixantrone effects on
topoisomerase IIa were qualitatively similar but quantita-
tively modest (9).
Pixantrone acts primarily by disrupting mitotic fidelity and
segregation of genomic material. This is shown by the for-
mation of lagging chromosomes, chromosomal bridges,
micronuclei and multinucleated cells. Apoptosis occurs after
3–4 waves of aberrant mitoses and is accompanied by lim-
ited accumulation of DNA double-strand breaks (10). Pix-
antrone is also able to alkylate DNA and to cause formation
of unusually long-lived adducts. This is favored by conjuga-
tion of pixantrone with formaldehyde that is formed in mea-
surable amounts in many cancer cells (11). Cause-and-effect
relations between persistent DNA damage and topoisomerase
IIa-independent missegregation events are likely to occur; in
fact, the mitotic checkpoint inhibitor, pChk1, enhances cellu-
lar effects of pixantrone (12).
Pixantrone-induced apoptosis is only in part relayed by
p53 (12). This finding anticipates a potential activity of pix-
antrone in non-Hodgkin lymphomas that harbor loss-of-func-
tion p53 mutations (13, 14); it also confirms that differences
exist between pixantrone and mitoxantrone, whose effects on
topoisomerase IIa inhibition and DNA damage are relayed
to apoptosis by p53 (15). Interestingly, however, recent stud-
ies maintain that pixantrone is a topoisomerase IIa inhibitor
(16). Data scrutiny shows that pixantrone inhibited topoiso-
merase IIa at concentrations exceeding its plasma Cmax in
lymphoma patients.
Clinical use of anthracyclines and mitoxantrone is limited
by a dose-related cardiotoxicity. Because anthracyclines are
eliminated incompletely from cardiac tissue, the risk of car-
diotoxicity extends lifetime (17). Sequential exposure to sub-
toxic doses of different anthracyclines, or sequential
exposure to an anthracycline and mitoxantrone, is therefore
limited by the risk of precipitating cardiotoxicity. Structural
similarities with mitoxantrone and intuitive classification in
the large group of anthracycline-like drugs raised concerns
that pixantrone caused cardiotoxicity but studies of anthracy-
cline-na€ıve or anthracycline-pretreated laboratory animals
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soon revealed that pixantrone was much less cardiotoxic
than doxorubicin or mitoxantrone and did not aggravate car-
diotoxicity in doxorubicin-pretreated animals (18).
Cardiotoxicity from anthracyclines and anthracenediones
is a multifactorial event that may be caused by excess for-
mation of reactive oxygen species and other free radicals, or
by inhibition of the b-isoform of topoisomerase II; anthracy-
clines are also known to convert into long-lived toxic
metabolites (15, 19). Postcrystallization studies of pix-
antrone–topoisomerase II b complexes, and functional assays
(16) suggest that pixantrone would not target cardiac
topoisomerase II b. In a translational model of human heart
pre-exposed to doxorubicin, pixantrone did not produce free
radicals but actually inhibited formation of the long-lived
and toxic doxorubicin metabolite, doxorubicinol. In compa-
rable settings, mitoxantrone did produce free radicals and
lacked inhibition of doxorubicinol formation (20). Pixantrone
generation of reactive oxygen species only occurs in cell
free systems that adopt high drug concentrations (16).
All such findings provide additional evidence to conclude
that pixantrone is different from mitoxantrone and anthracy-
clines.
Recommendations
Pixantrone monotherapy in aggressive relapsed or
refractory non-Hodgkin B-cell lymphomas
Early phase I or phase II trials with pixantrone. The stan-
dard approach for adult patients with aggressive NHL not
achieving a complete remission or relapsing after anthracy-
cline-based induction and eligible for intensive treatment
includes a salvage combination based on the anti-CD20
antibody rituximab (in CD20-positive NHL) and a non-
cross-resistant platinum-containing regimen. The most used
regimens are DHAP/DHAOX (dexamethasone, cytarabine,
and cisplatin/oxaliplatin), ICE (ifosfamide, carboplatin, eto-
poside), or ESHAP (methylprednisolone, etoposide, cytara-
bine, cisplatin). Responders to re-induction usually undergo
consolidation with high-dose therapy and autologous stem
cell transplantation (ASCT); in selected cases, allogeneic
stem cell transplantation (allo-SCT) may be considered. In
the planning of treatment for patients in this setting, one of
the trickiest issues that physicians have to face is progressive
myocardial toxicity related to the cumulative, dose-depen-
dent damage induced by anthracyclines, which may lead to
congestive heart failure (CHF).
Pixantrone was synthesized to provide similar antitumor
activity similar to the anthracyclines, but without the car-
diotoxicity. Three phase I dose-escalation single-agent stud-
ies (two in solid tumors and one in NHL/chronic
lymphocytic leukemia) explored two different treatment regi-
mens with pixantrone monotherapy: pixantrone every 3 wk
and pixantrone weekly for three consecutive weeks with
1-week rest (21–23). The final schedule selected for phase II
development was 85 mg/m2 of pixantrone on days 1, 8, and
15 of a 28-d cycle.
Following the promising results of pixantrone in earlier
trials, pixantrone has been tested as a single agent in a
prospective phase II study (24). Five patients achieved a
complete remission (CR) (15%) and nine had a partial
response (PR) (27%), with a median PFS of 106 d. Overall
response rate (ORR) was higher than that reported for sin-
gle-agent etoposide, cisplatin, or mitoxantrone.
Phase III randomized trial comparing pixantrone with sin-
gle-agent chemotherapy. The only phase III trial was an
international, multicenter, randomized, active-controlled,
open-label study reported by Pettengell and coworkers (PIX
301) and it led to drug registration by the EMA (5). The
study recruited patients with relapsed/refractory aggressive
or transformed NHL refractory to at least two prior regi-
mens, including at least one anthracycline-containing regi-
men (median cumulative dose of approximately 300 mg of
doxorubicin equivalents/m2). Patients were randomized
(1 : 1) to receive either pixantrone (with dose and schedule
identical to that used in the phase II setting) or single-agent
chemotherapy of the investigators choice, some of them
being: vinorelbine, ifosfamide, oxaliplatin, etoposide, gemc-
itabine, or mitoxantrone. The primary endpoints were CR
and complete remission unconfirmed (CRu) with PFS and
OS as secondary endpoints. The initial planned sample size
was 320 patients, but the study was subsequently closed
3 yr after the first patient was enrolled, with only 140
patients randomized (70 per arm) due to very slow accrual.
Most of the enrolled patients had diffuse large B-cell lym-
phoma (76% in the pixantrone arm vs. 73% in comparator
arm) or transformed indolent lymphoma (14% vs. 13%),
with a median age of 60 yr vs. 58 yr, mainly unfavorable
Ann Arbor stage and International Prognostic Index (IPI)
scores.
Patients living in countries where rituximab was available
were only eligible if they had received rituximab therapy. A
similar number of patients in each group had previously
received rituximab. Baseline patient characteristics were well
balanced in experimental and control arms. Seventy-one per-
cent of patients in the experimental arm and 76% in the
comparator arm did not complete the six planned cycles
because of disease progression or relapse (41% in the pix-
antrone group vs. 58% in the comparator group) or adverse
events (AEs) (22% vs. 13%, respectively). The response
analysis, based on the intention-to-treat population, showed
a benefit in terms of CR/CRu rate and ORR for pixantrone
(20% vs. 5.7%, P = 0.021; 37.1% vs. 14.3%, P = 0.003,
respectively). Median PFS was longer in the experimental
arm (5.3 months vs. 2.6 months, P = 0.005), and a trend
toward longer median OS was observed with pixantrone, but
this was not statistically significant (10.2 months vs.
7.6 months, P = 0.251). An exploratory analysis was
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performed to investigate whether any favorable factor pre-
dicting a better outcome was recognizable; an absence of
prior anti-CD20 treatment or stem cell transplantation, less
than three prior chemotherapy regimens, age ≥65 yr, and
female sex were identified as favorable prognostic factors,
but prior use of rituximab did not influence the benefit on
PFS.
In terms of toxicity, patients in the experimental arm
experienced more grade III and IV AEs (76.5% vs.
52.2%); however, the overall proportion of complications
was similar in the two groups (97.1% vs. 91%). No evi-
dence of cumulative, dose-related cardiotoxicity was
reported, and decreases in left ventricular ejection fraction
(LVEF) were not associated with clinical evidence of car-
diac impairment.
Critical appraisal of evidence and panel discussion on
appropriateness of pixantrone in advanced NHL. A critical
appraisal of evidence resulting from the randomized open-
label controlled clinical trial according to GRADE methodol-
ogy (6) is reported in the Supplement material. Two main
reasons for downgrading the quality of evidence supporting
the use of pixantrone in relapsed or refractory NHL were
highlighted. These were imprecision of the estimate of OS
and indirectness of the population treated in the trial. As a
matter of fact, the difference in OS between experimental
arm and control arm was not statistically significant. Conse-
quently, responders would not be judged responders using
OS. This discordance, reflecting indirectness of the OS out-
come measurement in the trial, could influence the confi-
dence in the effect size measurement because a proportion
of the responses were not clinically meaningful. Moreover,
the EMA approval of pixantrone did not specify an exclu-
sion for patients having previously received rituximab. Thus,
entry criteria of the trial differed substantially from the
EMA-approved therapy indication. Because of these two
issues, the risk of indirectness in the population being con-
sidered for therapy is high.
These conclusions were provided to the EP for discussion.
As far as imprecision in the estimate of OS, the EP reasoned
that the study was powered to look at response rate (RR)
and PFS (primary endpoints) and that, in the setting of
patients with relapsed/refractory NHL, RR and PFS were
deemed appropriate quality indicator of outcome. Thus, PFS
may well be intended as a surrogate for OS. Moreover, the
EP claimed that the real role of pixantrone therapy in multi-
ply relapsed refractory NHL patients is the potential ‘bridge’
to SCT, rendering OS outcome not so critical for these
patients in which the principal aim is to obtain a clinical
response (CR-CRu) to lead the patient (if eligible) to a con-
solidation SCT. In the EP’s opinion, the low precision level
in the estimate of OS for pixantrone superiority over investi-
gator’s choice in rituximab-treated patients neither affects
credibility of findings in PIX 301 study nor introduces con-
cerns in using pixantrone as per EMA recommendation.
As far as the indirectness of the population, the EP agreed
that the inclusion of rituximab-na€ıve patients in the study
represented a bias in the quality of evidence of pixantrone
activity. In fact, nowadays almost all patients would be
expected to have received previous rituximab, and previous
exposure to this antibody is known to be associated with a
decreased RR to subsequent chemotherapy. However, the EP
highlighted the evidence of poor outcome in the analysis of
patients na€ıve and non-na€ıve to rituximab derived from a
substudy, resulting in a very limited number of patients.
Despite this small number of patients, the RR in those previ-
ously exposed to rituximab was 1.76 (95% CI, 0.77–3.98).
This was not statistically significant but considered by the
EP as clinically relevant. The EP agreed that the results in
patients na€ıve to rituximab do not affect the overall credibil-
ity of findings in Pettengell’s study. The EP also acknowl-
edged that cost-effectiveness of pixantrone was positively
evaluated by NICE and others (25, 26).
Recommendations. According to EMA, pixantrone is indi-
cated for the treatment of adult patients with multiply
relapsed or refractory aggressive NHL B-cell lymphomas.
The EMA approval was based on only one randomized
trial whose evidence of the better benefit of pixantrone with
respect to available therapies was judged moderate. In partic-
ular, the evidence on the risk/benefit risk profile of the drug
was judged of lower quality in patients who had received a
previous rituximab therapy.
After a balanced and value-oriented discussion, the panel
agreed that the benefit/risk profile was in favor of pixantrone
in any category of patients despite the previous treatment
(recommendation of moderate strength).
Toxicity risk management in patients candidates to
pixantrone
During treatment with pixantrone as single agent in relapsed
aggressive NHL, grade 3–4 leukopenia and neutropenia were
the most relevant hematological toxicity (5, 24). These were
generally brief, lasting a median of 7.5 d, and did not increase
with the number of cycles, whereas grade 3–4 anemia or
thrombocytopenia was rarely observed. In particular, in the
Pettengels’s trial (5), grade III–IV neutropenia was more com-
mon in patients treated with pixantrone (41.2% vs. 19.4%), as
was febrile neutropenia (7.4% vs. 3.0%), while the rate of
thrombocytopenia was similar and that of anemia was lower
(11.8% vs. 10.4% and 5.9% vs. 13.4%, respectively).
In the open-label, non-randomized, non-comparative phase
II study (24), only three patients, two of whom with a previ-
ous low value of (LVEF), showed a ≥10% decrease in
LVEF measured by multigated acquisition scan. In one of
these, the treatment had to be discontinued when the patient
developed cardiac symptoms and LVEF decreased to 25%.
All of patients with cardiovascular toxicity were more than
65 yr of age and had received a prior anthracycline.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 557
Zinzani et al. Pixantrone in non-Hodgkin lymphomas
In the pivotal phase III trial (5), cardiac toxicity was
closely monitored, and a higher incidence of cardiac
events was seen in the pixantrone group (35% vs. 21%).
Only 13% cases of cardiac events were considered related
to pixantrone, and all were asymptomatic decreases in
LVEF. No clear cases of pixantrone-associated CHF were
reported, and importantly, cardiac events did not correlate
with the cumulative dose of pixantrone. This latter finding
denoted differences between pixantrone and anthracyclines,
whose cardiotoxicity typically develops in a dose-related
manner. Five patients in the experimental arm had a
previous history of CHF or continuing cardiomyopathy at
the time of enrollment, whereas none of the patients in
the comparator group had a history of these conditions.
Such an unbalanced representation of cardiac risk factors
in the two study arms could have at least in part con-
tributed to the observed higher incidence of cardiac
adverse events in patients randomized to pixantrone. Over-
all, pixantrone cardiotoxicity is judged to be acceptable,
especially if one appreciates that patients had been previ-
ously exposed to a median cumulative doxorubicin dose
of approximately 300 mg/m2. The acceptable cardiotoxicity
of pixantrone is confirmed by the Periodic Safety Report
(PSUR) that summarizes pixantrone safety data from both
clinical and commercial data, the vast majority of cardiac
events attributed to pixantrone being coded ‘investigations’
(ejection fraction decreased) rather than cardiac disorders
(27).
Clinical and health conditions more frequently related
to cardiovascular events during pixantrone administration
are the age greater than 65 yr, the low LVEF value
before therapy, the previous history of CHF, and
cardiomyopathy.
No evidence was reported for the efficacy of cardiovascu-
lar prophylaxis in patients candidates to pixantrone and car-
rying these risk factors. No recommendations for
prophylaxis or treatment of cardiac toxicity were reported.
Recommendations
The EP agreed that neutropenia ensuing after pixantrone sin-
gle-agent therapy should be managed by G-CSF prophylaxis
as for other NHL chemotherapy regimens (28).
Pixantrone is contraindicated in patients with uncontrolled
cardiovascular disease.
All patients without cardiovascular disease or with a con-
trolled cardiovascular disease who are candidates for pix-
antrone therapy should undergo a cardiological evaluation
including electrocardiogram and echocardiogram. There are
no indications to cardiovascular prophylaxis in patients with-
out cardiovascular disease.
In patients on treatment for cardiovascular disease, the
appropriateness of cardiovascular therapy should be verified
before pixantrone therapy.
Despite a low rate of cardiotoxicity of pixantrone reported
in clinical trials, the EP recommended that all patients
receiving pixantrone should undergo periodical cardiac mon-
itoring.
If cardiac toxicity is demonstrated during treatment (grade
two cardiac toxicity (29) or significant decrease in LVEF),
the individual risk/benefit ratio of continuing pixantrone
therapy should be evaluated.
Research perspectives
Pixantrone combination therapy in relapsed or
refractory non-Hodgkin B-cell lymphomas
Four studies have investigated pixantrone as part of a poly-
chemotherapeutic regimen, in patients with relapsed NHL.
Three studies included patients with aggressive NHL, and
one study included patients with indolent NHL. Three stud-
ies were reported in full papers while one in abstract form
(30–33) (Table 1). Taken overall, the responses ranged from
58% to 73%. Cardiotoxicity rates ranged from 7% to 19%
with limited grade II-IV toxicities (2–3%). These results
Table 1 Studies using pixantrone in combination therapy for patients with refractory or resistant aggressive NHL
Study Design Combination
Number of
patients
treated
Media number
of cycles
administered
ORR,
n (%)
CR,
n (%)
PR,
n (%)
Median
PFS OS
Lim et al.,
(2007) (30)
Phase I/II PSHAP 19 4 (1–6) 11 (58) 7 (37) 4 (21) 5.7 months Median:
14.7 months
Borchman et al.,
(2011) (31)
Phase I/II CPOP 65 6 (1–6) 47 (72) 30 (46) 17 (26) 8.2 months Median:
17.9 months
d’Amore et al.,
(2014) (32)
Preliminary
clinical
experience
PREBEN/
PEBEN
8 3 (2–6) 6 (62.5) 3 (37.5) 2 (25)
Srokowski et al.,
(2011) (33)
Dose-escalation
phase I study
FPD-R 27 5 (1–8) 19 (70) 12 (44) 7 (26) 2 and
3-yr: 91.5%
PSHAP, pixantrone, methylprednisolone, high-dose cytarabine, cisplatin; CPOP, cyclophosphamide, pixantrone, vincristine, prednisone; FPD-R,
fludarabine, pixantrone, dexamethasone, rituximab; PREBEN/PEBEN, etoposide, bendamustine, pixantrone (rituximab).
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suggest that pixantrone can be further evaluated in combina-
tion studies.
Ideal candidates for combination therapy with pixantrone
in NHL should target molecular pathways other than those
of pixantrone or should be able to remove molecular barriers
to the action of pixantrone. Combination agents and pix-
antrone would therefore elicit synergistic rather than additive
effects in tumor cells. The finding that clinically relevant
concentrations of pixantrone lacked inhibition of topoiso-
merase IIa anticipates that non-anthracycline topoisomerase
IIa inhibitors would synergize with pixantrone in tumor
cells. The epipodophyllotoxin, etoposide, is a general topoi-
somerase inhibitor that should be considered for combination
with pixantrone. Other combination strategies might adopt
inhibitors of mitotic checkpoints. The mixed antimetabolite
alkylator, bendamustine, warrants consideration as it induces
a complex stress response that downregulates the activity of
numerous mitotic checkpoints (34).
Among the combination therapies including pixantrone,
only one trial fitted this rationale. d’Amore and coworkers
(32) explored a combination chemotherapy regimen based
on pixantrone in patients with multiply relapsed or refractory
aggressive B and T non-Hodgkin lymphoma in which etopo-
side and bendamustine were chosen as companion com-
pounds. Rituximab was added in patients with B-cell
lymphoma. The adapted schedule consisted of pixantrone
50 mg/m2 i.v. day 1 + 8, etoposide 100 mg i.v. day 1, ben-
damustine 90 mg/m2 i.v. day 1 with or without the addition
of rituximab 375 mg/m2 i.v. day 1 (PREBEN/PEBEN). If
feasible, each cycle was given at 3-weekly intervals for a
maximum of six cycles. Three patients (25%) achieved a CR
and 2 (50%) obtained a partial response (ORR 62.5%). One
trial with ongoing enrollment is registered on ClinicalTrials.-
gov (NCT 01491841) aimed at testing bendamustine, ritux-
imab, and pixantrone in a phase I/II trial in patients with
relapsed/refractory B-cell NHL.
Two other relevant trials are registered on the ClinicalTri-
als.gov website, both concerning the treatment of relapsed
refractory B-cell NHL. The first study investigates relapsed
diffuse large B-cell lymphoma, transformed from indolent
lymphoma, and follicular grade III lymphoma not eligible
for SCT. This phase III, multicenter, randomized trial is
comparing a pixantrone–rituximab regimen with a gemc-
itabine–rituximab regimen, with a planned sample size of
350 patients (NCT01321541). The second one was aimed to
evaluate the ORR of obinutuzumab (GA101) in combination
with pixantrone. Seventy patients will receive up to six
cycles of the regimen. (NCT02499003).
Pixantrone combination therapy in untreated DLBC
lymphoma
Herbrecht and coworkers initiated a phase II multicenter,
randomized controlled trial in untreated patients with stage
II-IV DLBCL substituting doxorubicin with pixantrone
(150 mg/m2) in R-CHOP (R-CPOP) (35). After four cycles,
patients with a (PR) received four more cycles of treatment;
those with CR received two more cycles. The primary objec-
tive of the trial was to show non-inferiority of R-CPOP to
R-CHOP, and secondary endpoints included ORR, PFS, OS,
and safety. The study recruited 124 from the preplanned 280
patients needed, due to financial constraints. Of the 124
patients enrolled, 61 were randomized to R-CPOP and 63 to
R-CHOP. In terms of efficacy, there were no statistically sig-
nificant differences between the two regimens. CR rate in
the intent-to-treat population was 72.1% for R-CPOP vs.
79.4% for R-CHOP, and ORR was 82% vs. 87.3%. Median
PFS was not reached in the CPOP-R arm and was
40 months in the CHOP-R arm; median OS was not reached
in either treatment arm. OS rates were lower for patients
treated with CPOP-R (hazard ratio 2.37, P = 0.029), with
more deaths occurring in the CPOP-R arm (30% vs. 14%).
Overall, AEs were similar in approximately 85% of patients
in both arms. Non-inferiority could not be demonstrated due
to early closure of the trial due to financial constraints.
Despite this, efficacy was comparable between the two arms,
but R-CPOP showed a reduced cardiotoxicity measured by
echocardiography or circulating levels of troponin.
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